Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy
- 15 December 1992
- Vol. 70 (12) , 2870-2878
- https://doi.org/10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Secretion of inhibin‐like material by rat ventral prostate epithelial cells in cultureThe Prostate, 1991
- Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.Journal of Clinical Oncology, 1990
- Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation ConceptPublished by Springer Nature ,1988
- Retinoic acid (RA): An inhibitor of 5α-reductase in human prostatic cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1987
- Clinical Trials in Prostatic Cancer: Methodology and ControversiesPublished by Springer Nature ,1987
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.Journal of Clinical Oncology, 1985
- Phase II Trial of Doxorubicin in Bidimensionally Measurable Prostatic AdenocarcinomaJournal of Urology, 1984
- The Treatment of Oestrogen-Escaped Carcionoma of the Prostate with Estramustine PhosphateBritish Journal of Urology, 1977
- A Comparison of Estramustine Phosphate and Streptozotocin in Patients with Advanced Prostatic Carcinoma Who Have Had Extensive IrradiationJournal of Urology, 1977